Research Summary

My research program is focused on imaging cancer using MRI and novel PET tracers. At UCSF, I have developed the gallium-68 DOTA-TOC imaging program for neuroendocrine tumor staging, and am the principle investigator on the FDA IND. I have also successfully brought Ga-68 PSMA imaging to UCSF and am currently drafting the IND submission to allow for the evaluation of the clinical use of this agent. I am interested in using somatostatin receptor and PSMA based PET agents in order to distinguish neuroendocrine prostate cancer from adenocarcinoma. Additionally, I believe that the combination of MR and PET parameters will aid in the staging of cancers. Most straightforward is a study we are carrying out in low risk prostatectomy patients where we are evaluating the use of PET/MRI using Ga-68 PSMA and MR imaging of the primary tumor. In the setting of patients with metastatic disease, PET/MRI will likely have an even more important role, as response to treatment will change uptake of non-FDG tracers in ways that are not immediately clear and intepretation will likely rely on changes in MR imaging parameters such as diffusion weighted imaging (DWI).

Research Funding

  • July 1, 2019 - June 30, 2025 - MELT: Modulation of PSMA Expression for Lutetium Therapy , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA235741
  • March 6, 2017 - February 28, 2023 - Qualification and Harmonization of PET/MRI for Cancer Clinical Trials , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA212148
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA229354

Education

Duke University, Durham, NC, BA/BS, 6/2001, Biology, Economics
Stanford University, MD, 6/2007 Medicine
Kaiser San Francisco, 6/2008, Internal Medicine
University of California, San Francisco, 6/2012, Diagnostic Radiology Residency
Stanford University, 6/2013, Body MRI/nuclear medicine Fellowship

Honors & Awards

  • 2001
    Summa Cum Laude, Duke University
  • 2001
    Phi Beta Kappa, Duke University
  • 2006
    Trainee Research Prize, Radiological Society of North America
  • 2007
    W. S. Moore Award, Nominee, International Society of Magnetic Resonance in Medicine
  • 2011
    Magnum Cum Laude Merit Award, International Society of Magnetic Resonance in Medicine
  • 2012
    Roentgen Resident/Fellow Research Award, Radiological Society of North America
  • 2012
    Alexander Margulis Society Excellence in Research Award, UCSF
  • 2014
    Wylie J. Dodds Research Award, Society of Abdominal Radiology

Selected Publications

  1. Konstantinoff KS, Morani AC, Hope TA, Bhosale PR, Francis IR, Yano M, Iravani A, Trikalinos NA, Itani M. Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios. Abdom Radiol (NY). 2023 Feb 04.  View on PubMed
  2. Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Ta?eb D, Kjaer A. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 Feb; 64(2):204-210.  View on PubMed
  3. Garje R, Hope TA, Rumble RB, Parikh RA, Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer . Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A. JCO Oncol Pract. 2023 Jan 24; OP2200753.  View on PubMed
  4. Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Sch?der H, Wan S, Wester HJ, Hope TA, Herrmann K. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 Jan 05.  View on PubMed
  5. Sabbagh A, Mohamad O, Lichter KE, Hope TA. Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET. Cancers (Basel). 2022 Dec 15; 14(24).  View on PubMed
  6. Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P, Siva S, Hofman MS, Murphy DG, Emmett L, Fendler WP. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023 Jan; 20(1):23-47.  View on PubMed
  7. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2022 Nov 24.  View on PubMed
  8. Tranel J, Palm S, Graves SA, Feng FY, Hope TA. Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model. EJNMMI Phys. 2022 Sep 30; 9(1):67.  View on PubMed
  9. Polvoy I, Seo Y, Parker M, Stewart M, Siddiqua K, Manacsa HS, Ravanfar V, Blecha J, Hope TA, Vanbrocklin H, Flavell RR, Barry J, Hansen E, Villanueva-Meyer JE, Engel J, Rosenberg OS, Wilson DM, Ohliger MA. Imaging joint infections using D-methyl-11C-methionine PET/MRI: initial experience in humans. Eur J Nucl Med Mol Imaging. 2022 09; 49(11):3761-3771.  View on PubMed
  10. Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Clin Nucl Med. 2022 Jun 01; 47(6):503-511.  View on PubMed
  11. Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol. 2022 08 20; 40(24):2818-2829.  View on PubMed
  12. Jha A, Patel M, Carrasquillo JA, Chen CC, Millo C, Maass-Moreno R, Ling A, Lin FI, Lechan RM, Hope TA, Ta?eb D, Civelek AC, Pacak K. Choice Is Good at Times: The Emergence of [64Cu]Cu-DOTATATE-Based Somatostatin Receptor Imaging in the Era of [68Ga]Ga-DOTATATE. J Nucl Med. 2022 09; 63(9):1300-1301.  View on PubMed
  13. Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Am J Clin Oncol. 2022 06 01; 45(6):233-242.  View on PubMed
  14. Hope TA, Jadvar H. Updates to Appropriate Use Criteria for PSMA PET. J Nucl Med. 2022 05; 63(5):14N.  View on PubMed
  15. Simon NI, Parker C, Hope TA, Paller CJ. Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-8.  View on PubMed
  16. Mailman J, Hope TA. Leadership in Patient Advocacy: A Conversation Between Josh Mailman and Thomas Hope. J Nucl Med. 2022 04; 63(4):497-499.  View on PubMed
  17. Hope TA, Calais J. PSMA PET in Prostate Cancer-A Biomarker or a Surrogate End Point?-Reply. JAMA Oncol. 2022 04 01; 8(4):1.  View on PubMed
  18. Leach JR, Shen H, Huo E, Hope TA, Mitsouras D, Whooley MA, Hope MD. Impact of Implicit Abdominal Aortic Aneurysm Screening in the Veterans Affairs Health Care System Over 10 Years. J Am Heart Assoc. 2022 04 05; 11(7):e024571.  View on PubMed
  19. Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D, Sheehan-Dare G, Alghazo O, Agrawal S, Murphy D, Stricker P, Hope TA, Hofman MS. The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022 11; 63(11):1644-1650.  View on PubMed
  20. Sgouros G, Dewaraja YK, Escorcia F, Graves SA, Hope TA, Iravani A, Pandit-Taskar N, Saboury B, James SS, Zanzonico PB. Reply: Single-Time-Point Tumor Dosimetry Assuming Normal Distribution of Tumor Kinetics. J Nucl Med. 2022 05; 63(5):804.  View on PubMed

Go to UCSF Profiles, powered by CTSI